SABCS 2025

Important new data for young breast cancer patients

Firstline treatment of MBC: Which strategy is best?

Axilla dissection - less is more

Giredestrant will replace current adjuvant therapy

Revolution in adjuvant endocrine therapy?

ALTTO trial outcome according to endocrine therapy

Therapy optimization: Endocrine approaches in…

Surgery remains soc in low risk EBC

PALLAS trial and ctDNA

AI based prognostic test

SERDs now in adjuvant therapy

ctDNA analysis could optimize the approach in HER2+

Quality of live data DB11

Significant innovations in early and metastatic HER2+…

Optimized endocrine therapy for premenopausal patients

Safety data DB11

Olaparib neoadjuvant with high PCR rates

Carboplatin in adjuvant setting of TNBC

Platinum adjuvant in TNBC

La chirurgia rimane lo standard di cura nei casi di…

SERDy we wczesnym raku piersi -początek nowej epoki?

Risultati dello studio ALTTO in base alla terapia…

Otimização da terapia: abordagens endócrinas em…

El análisis del ADN libre circulante podría optimizar…

Updated results of VIKTORIA-1

The significance of SG is more clearly defined

Phase 2 combination of elacestrant with everolimus or…

Biomarker and clinical subgroup analysis of evERA…

Chemotherapy-free treatment: a promising therapeutic…

No improvement over standard therapy

Elacestrant is a good combination partner for HR+ HER2+…

ASCENT-07 a negative trial

Elacestrant as oral endocrine backbone

Triple-positive MBC: less chemotherapy, more endocrine…

Make a hot tumor out of a cold tumor

Palbociclib likely delays CNS progression

Significant innovations in early and metastatic HER2+…

Maintenance therapy HER2+ Tucatinib as a new option

Tucatinib a new SERD in the adjuvant setting

ctDNA Dynamics as a biomarker of response

CDK4/6 inhibitor + endocrine therapy remains the…

Monitoring of ILD

Sem melhorias em relação à terapia padrão

Jeszcze nie czas na rezygnację z tradycyjnej…

Nuove prove a favore dei SERD orali

Résultats actualisés de VIKTORIA-1

Tucatinib, un nouveau SERD dans le cadre d'un…

Risultati aggiornati di VIKTORIA-1

Elacestrant come partner endocrino orale